Dive Brief:

潜水简介：

Uwe Schoenbeck, a biotech veteran who most recently was chief scientific officer at Pfizer’s innovation division, has joined Canaan Partners as a venture partner, the investment firm announced Wednesday.

辉瑞周三宣布，生物技术资深人士Uwe Schoenbeck（最近担任辉瑞创新部门首席科学官）已加入加拿大合作伙伴（Canaan Partners）成为风险合作伙伴。

Since starting at Canaan in January, Schoenbeck has led Canaan’s involvement in a $132 million Series B round for precision cancer drug developer Alterome Therapeutics.

自1月在迦南开始以来，Schoenbeck领导迦南参与了一轮1.32亿美元的B系列精准癌症药物开发项目Alterome Therapeutics。

The firm also said Friday it has raised another $100 million to invest in technology and healthcare companies, bringing its total raised to more than $1 billion since launching a new fund in early 2023.

该公司周五还表示，它已经筹集了1亿美元用于投资科技和医疗保健公司，自2023年初启动新基金以来，募集资金总额已超过10亿美元。

Dive Insight:

潜水洞察：

Canaan has been an active biotech investor over the past three years, backing companies like cough drug developer Nocion Therapeutics and a cancer drugmaker founded by Craig Crews called Halda Therapeutics. The firm expects Schoenbeck to help accelerate that activity.

过去三年来，迦南一直是一位活跃的生物技术投资者，支持咳嗽药物开发公司Nocion Therapeutics和克雷格·克鲁斯（CraigCrews）创立的一家名为Halda Therapeutics的癌症药物制造商。该公司希望Schoenbeck能够帮助加速这一活动。

“It is not often that we have the opportunity to add someone of [Schoenbeck’s] caliber and track record to the Canaan investment team,” Tim Shannon, general partner at Canaan, said in a statement. “He is a particularly good fit for Canaan as he shares our vision for how to identify breakthrough science, team with entrepreneurs, create and support biopharma companies, and, ultimately, advance patient care.”.

“我们很少有机会在迦南投资团队中加入具有（肖恩贝克）才能和业绩记录的人，”迦南普通合伙人蒂姆·香农（TimShannon）在一份声明中表示。“他特别适合迦南，因为他分享了我们关于如何识别突破性科学、与企业家合作、创建和支持生物制药公司以及最终推进患者护理的愿景。”。

At Pfizer, Schoenbeck led the company’s Emerging Science & Innovation unit, which included the Centers for Therapeutic Innovation, an academic partnering group that brought forward medicines like a gut disease drug licensed to a Roivant Sciences subsidiary. The group was recently shuttered, Fierce Biotech reported Wednesday..

在辉瑞，Schoenbeck领导该公司新兴的科学与创新部门，其中包括治疗创新中心，这是一个学术合作团体，该团体向Roivant Sciences子公司提供肠道疾病药物等药物。凶猛生物科技周三报道称，该集团最近被关闭。。

Schoenbeck also sat on the board of directors of CQDM, a pharmaceutical consortium designed to bring early research into the industry. The effort involved companies such as Pfizer, AstraZeneca and GSK, as well as the Canadian government.

Schoenbeck还是CQDM的董事会成员，CQDM是一个旨在将早期研究带入该行业的制药财团。这项工作涉及辉瑞（Pfizer）、阿斯利康（AstraZeneca）和葛兰素史克（GSK）等公司以及加拿大政府。

Previously, Schoenbeck was a vice president at Wyeth and Boehringer Ingelheim, and a professor at Brigham & Women’s Hospital, Harvard Medical School.

此前，勋贝克曾任惠氏和勃林格殷格翰公司副总裁，哈佛医学院布莱根妇女医院教授。

Canaan first worked with Schoenbeck while he was at Pfizer, collaborating on an investment in Arrakis Therapeutics and a deal with Arvinas. In an interview, he said his decision to enter venture capital will give him a chance to return to his “hands-on” roots as a scientist and advance drugs at the early stages of their development..

卡南在辉瑞（Pfizer）任职期间，首先与肖恩贝克（Schoenbeck）合作，投资Arrakis Therapeutics，并与Arvinas达成协议。在一次采访中，他表示，他进入风险投资的决定将给他一个机会，让他有机会回到自己作为科学家的“动手”根源，并在药物开发的早期阶段推进药物。。

“Interest from mid- and large-sized pharma has focused on de-risked assets,' Schoenbeck said. 'A lot of our investments are in that range, enabling those studies, but I would also expect in years to come there will be some rebalancing in regards to early platforms and technologies.”

Schoenbeck说：“中大型制药公司的兴趣集中在降低风险的资产上。我们的许多投资都在这一范围内，这使得这些研究成为可能，但我也预计未来几年将在早期平台和技术方面进行一些重新平衡。”